PAPILLARY THYROID CARCINOMA FOLLOWING ADALIMUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: A CAUSAL OR COINCIDENTAL ASSOCIATION?

Basit Öğe Kaydı
dc.contributor.authorUslu, S.
dc.date.accessioned2024-11-07T10:40:03Z
dc.date.available2024-11-07T10:40:03Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractThe introduction of tumor necrosis factor-alpha (TNF-?) targeting drugs has given new opportunities in the treatment of various inflammatory rheumatic diseases and has been the most important development in the treatment of ankylosing spondylitis (AS). However, the increasing use and longer follow-up periods of treatment also pose risks of developing various adverse effects, ranging from common ones, including infections, to uncommon thyroid neoplasms. Adalimumab (ADA), a fully human monoclonal antibody targeted against TNF-?, is indicated for AS. We describe the case of a patient with AS who developed a papillary thyroid carcinoma (PTC) while on therapy with ADA. Cervical lymphadenopathy and a heterogeneous nodule in the right thyroid lobe were detected in the 48-year-old female patient who had been using ADA (40 mg subcutaneously every 2 weeks) for 2 years with the diagnosis of AS. Fine-needle aspiration cytology confirmed PTC. ADA treatment was discontinued, and a total thyroidectomy surgery was performed. We believe that the thyroid gland should also be taken into consideration while screening for malignancy before and during TNF inhibitors (TNFi). has been approved for use in the treatment of AS. However, the use of these agents has been shown to be associated with multiple potential adverse effects (2). TNF inhibitors (TNFi) are known to have rare side effects, including autoimmune conditions that resemble lupus, vasculitis, inflammatory pulmonary disease, sarcoidosis, psoriasis, uveitis, demyelinating neurological conditions, and autoimmune hepatitis. These side effects may also include infections and lymphoma. Rarely, TNFi medications may be linked to thyroid neoplasms (3). We aimed to discuss a case of papillary thyroid carcinoma (PTC) presenting with clinically asymptomatic cervical swelling after 24 months of ADA treatment. © 2023, Acta Endocrinologica Foundation. All rights reserved.
dc.identifier.doi10.4183/aeb.2023.376
dc.identifier.endpage379
dc.identifier.issn1841-0987
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85184458235
dc.identifier.scopusqualityQ4
dc.identifier.startpage376
dc.identifier.urihttps://doi.org/10.4183/aeb.2023.376
dc.identifier.urihttps://hdl.handle.net/11480/11394
dc.identifier.volume19
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherActa Endocrinologica Foundation
dc.relation.ispartofActa Endocrinologica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectAdalimumab
dc.subjectAnkylosing spondylitis
dc.subjectPapillary thyroid carcinoma
dc.subjectTNF inhibitors
dc.titlePAPILLARY THYROID CARCINOMA FOLLOWING ADALIMUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: A CAUSAL OR COINCIDENTAL ASSOCIATION?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu